# | Age | Sex | Medications | Treatment duration |
Ref | Link | ||
---|---|---|---|---|---|---|---|---|
1 | 28 years | MtF | CPA 100 mg/day, EE 100 μg/day | 5 years | Gazzeri et al. (2007) | [1] | ||
2 | 48 years | MtF | CPA 100 mg/day, EE ("feminizing regimen") | 10 years | Cebula et al. (2010) | [2] | ||
3 | 46 years | Female | CPA 50 mg/day, E2 ("substitutive") | 10 years | Gonçalves et al. (2010) | [3] | ||
4 | 83 years | Male | CPA ≥50 mg/day | 2 years | Gil et al. (2011) | [4] | ||
5 | 71 years | Male | CPA ≥50 mg/day | 3 years | Gil et al. (2011) | [4] | ||
6 | 66 years | Female | CPA ≥50 mg/day | 3 years | Gil et al. (2011) | [4] | ||
7 | 43 years | Female | CPA ≥50 mg/day | 2 years | Gil et al. (2011) | [4] | ||
8 | 35 years | MtF | CPA 100 mg/day, E2 100 μg/day patch | 4 years | Bergoglio et al. (2012) | [5] | ||
9 | 60 years | MtF | CPA 50 mg/day, E2 8 mg/day oral | 10 years | Knight et al. (2013) | [6] | ||
10 | 56 years | MtF | CPA, EV 2 mg/day oral | 8 years | Razavi (2014) | [7] | ||
11 | 51 years | Female | CPA 15 mg/day | 30 years | Bernat et al. (2015) | [8] | ||
12 | 47 years | Female | CPA 25 mg/day | 15 years | Bernat et al. (2015) | [8] | ||
13 | 43 years | Female | CPA 50 mg/day | 12 years | Bernat et al. (2015) | [8] | ||
14 | 39 years | Female | CPA 50 mg/day | 10 years | Bernat et al. (2015) | [8] | ||
15 | 61 years | Female | CPA 25 mg/day | 24 years | Bernat et al. (2015) | [8] | ||
16 | 38 years | Female | CPA 25 mg/day | 10 years | Bernat et al. (2015) | [8] | ||
17 | 45 years | Female | CPA 50 mg/day | 20 years | Bernat et al. (2015) | [8] | ||
18 | 53 years | Female | CPA 50 mg/day | 20 years | Bernat et al. (2015) | [8] | ||
19 | 56 years | Female | CPA 50 mg/day | 8 years | Bernat et al. (2015) | [8] | ||
20 | 55 years | Female | CPA 50 mg/day | 30 years | Bernat et al. (2015) | [8] | ||
21 | 49 years | Female | CPA 50 mg/day | 20 years | Bernat et al. (2015) | [8] | ||
22 | 49 years | Female | CPA 50 mg/day | 25 years | Bernat et al. (2015) | [8] | ||
23 | 58 years | Female | CPA 50 mg/day | 18 years | Botella et al. (2015) | [9] | ||
24 | 37 years | Female | CPA 50 mg/day | 11 years | Botella et al. (2015) | [9] | ||
25 | 42 years | Male | CPA 100 mg/day | 23 years | Sys & Kestelyn (2015) | [10] | ||
26 | 45 / 46 years | MtF | CPA 10 or 100 mg/day, E2 20 mg/4 months implant | 5 years | ter Wengel et al. (2015) | [11][12] | ||
27 | 51 years | MtF | CPA 100 mg/day, EE 100 μg/day | 25 years | ter Wengel et al. (2015) | [11][12] | ||
28 | 65 years | MtF | CPA 10 mg/day, CEEs 1.25 mg/day | 19 years | ter Wengel et al. (2015) | [11][12] | ||
29 | 26 years | Female | CPA 50 mg/day | 10 years | Kalamarides & Peyre (2017) | [13] | ||
30 | 43 years | Female | CPA 25 mg/day | 25 years | Kalamarides & Peyre (2017) | [13] | ||
31 | 83 years | Male | CPA 200 mg/day | 7 months | Keilani & Abada (2017) | [14] | ||
32 | 65 years | Female | CPA 50 mg/day | 15 years | Bernat et al. (2018) | [15] | ||
33 | 77 years | MtF | CPA 50 mg/day, E2 50 μg/day patch | 24 years | Boer et al. (2018) | [16] | ||
34 | 41 years | MtF | CPA 50 mg/day, E2 gel 1–3 mg/day | 9 years | Mancini et al. (2018) | [17] | ||
35 | 60 years | MtF | CPA, CEEs | 36 years | Nizar & Seal (2018) | [18] | ||
36 | 51 years | MtF | CPA 20 mg/week, E2 100 μg/day patch | 11 years | Nota et al. (2018) | [12] | ||
37 | 66 years | MtF | CPA 10 mg/day | 40 years | Nota et al. (2018) | [12] | ||
38 | 58 years | MtF | CPA 50 mg/day, E2 100 μg/day patch | 6 years | Nota et al. (2018) | [12] | ||
39 | 49 years | MtF | CPA, EV 2 mg/day | 16 years | Nota et al. (2018) | [12] | ||
40 | 51 years | MtF | CPA 100 mg/day, EE 100 μg/day patch | 26 years | Nota et al. (2018) | [12] | ||
41 | 50 years | MtF | CPA 50 mg/day, E2 0.6 mg/g cream 2x/day | ~10 years | Raj et al. (2018) | [19] | ||
42 | 48 years | MtF | CPA 50 mg/day, E2 1 mg/g cream 3x/day | 21 years | Raj et al. (2018) | [19] | ||
43 | 43 years | Female | CPA 25–50 mg/day, EV 2 mg/day, finasteride 5 mg/day, others | 23 years | Chasseur et al. (2019) | [20] | ||
44 | 67 years | MtF | CPA, estrogen | >14 years | Alalade et al. (2019) | [21] | ||
45 | 46 years | Female | CPA 5 mg/day, subsequently NOMAC 5 mg/day | 15 years | Champagne et al. (2019) | [22] | ||
46 | 58 years | Female | CPA 25–100 mg/day for 10 days/cycle | 34 years | Owens et al. (2019) | [23] | ||
47 | ? | Male | CPA 300 mg/2 weeks i.m., leuprorelin 11.25 mg/3 months i.m. | ? | Colstrup et al. (2020) | [24] | ||
Abbreviations: CPA = Cyproterone acetate. E2 = Estradiol. EV = Estradiol valerate. CEEs = Conjugated estrogens. EE = Ethinylestradiol. MtF = Male-to-female (transgender woman). Notes: For the Bernat et al. (2015) cases, only one was reported to be taking an estrogen (specifically estradiol).[8] Froelich et al. (2008) reported an additional 8 female cases (age 33–62 years, mean 46 years; 50 mg/day CPA; 10–20 years exposure) with multiple meningiomas.[25] Cea-Soriano et al. (2012) also reported 8 cases (4 male (≥50 mg/day, OR = 3.28), 4 female (2 mg/day, OR = 1.03)) with no individual specifics.[9][26] Peyre et al. reported 38 operated cases.[27] Portet et al. (2019) reported 30 operated cases.[28] Cases in association with other progestins have been reported as well.[8] Deipolyi, Han, & Parsa (2010) reported a case in an MtF in association with E2 100 μg/day only.[29] Sources: [11][17][30] |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/4/43/Test_Template_Info-Icon_-_Version_%282%29.svg/50px-Test_Template_Info-Icon_-_Version_%282%29.svg.png)
See also
References
- ^ Gazzeri R, Galarza M, Gazzeri G (December 2007). "Growth of a meningioma in a transsexual patient after estrogen-progestin therapy". N. Engl. J. Med. 357 (23): 2411–2. doi:10.1056/NEJMc071938. PMID 18057351.
- ^ Cebula H, Pham TQ, Boyer P, Froelich S (November 2010). "Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient". Acta Neurochir (Wien). 152 (11): 1955–6. doi:10.1007/s00701-010-0787-2. PMID 20811919. S2CID 947448.
- ^ Gonçalves AM, Page P, Domigo V, Méder JF, Oppenheim C (September 2010). "Abrupt regression of a meningioma after discontinuation of cyproterone treatment". AJNR Am J Neuroradiol. 31 (8): 1504–5. doi:10.3174/ajnr.A1978. PMID 20053802. S2CID 14800959.
- ^ a b c d Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ (December 2011). "Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study". Br J Clin Pharmacol. 72 (6): 965–8. doi:10.1111/j.1365-2125.2011.04031.x. PMC 3244644. PMID 21627676.
- ^ Bergoglio MT, Gómez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernández-Mijares A (May 2013). "Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual". Endocrinol Nutr. 60 (5): 264–7. doi:10.1016/j.endonu.2012.07.004. PMID 23022362.
- ^ Knight, Ema J.; McDonald, Matthew J. (2013). "Recurrence and Progression of Meningioma in Male-to-Female Transgender Individuals During Exogenous Hormone Use". International Journal of Transgenderism. 14 (1): 18–23. doi:10.1080/15532739.2012.725563. ISSN 1553-2739. S2CID 56492694.
- ^ Razavi, Hamid Borghei (2014). "Meningioma: The Unusual Growth in a Transsexual Patient after Estrogen-Progesterone Therapy". SOJ Neurology. 1 (2). doi:10.15226/2374-6858/1/2/00109. ISSN 2374-6858.
- ^ a b c d e f g h i j k l m n Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (October 2015). "Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients". Acta Neurochir (Wien). 157 (10): 1741–6. doi:10.1007/s00701-015-2532-3. PMID 26264069. S2CID 27512648.
- ^ a b c Botella C, Coll G, Lemaire JJ, Irthum B (October 2015). "Méningiomes intracrâniens et utilisation prolongée d'acétate de cyprotérone à dose conventionnelle chez la femme : à propos de deux cas de régression tumorale après arrêt du traitement" [Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal]. Neurochirurgie (in French). 61 (5): 339–42. doi:10.1016/j.neuchi.2015.05.002. PMID 26249273.
- ^ Sys C, Kestelyn P (2015). "Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate". GMS Ophthalmol Cases. 5: Doc05. doi:10.3205/oc000027. PMC 5015623. PMID 27625949.
- ^ a b c d Ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM (December 2016). "Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature". Andrologia. 48 (10): 1130–1137. doi:10.1111/and.12550. PMID 26888610. S2CID 10465392.
- ^ a b c d e f g h Nota NM, Wiepjes CM, de Blok C, Gooren LJ, Peerdeman SM, Kreukels B, den Heijer M (July 2018). "The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment". Brain. 141 (7): 2047–2054. doi:10.1093/brain/awy108. PMID 29688280.
- ^ a b Kalamarides M, Peyre M (May 2017). "Dramatic Shrinkage with Reduced Vascularization of Large Meningiomas After Cessation of Progestin Treatment". World Neurosurg. 101: 814.e7–814.e10. doi:10.1016/j.wneu.2017.03.013. PMID 28300711.
- ^ Keilani C, Abada S (May 2017). "An uncommon case of symptomatic multiple meningiomas with bilateral compressive optic neuropathy rapidly induced under cyproterone acetate treatment". Curr Drug Saf. 12 (2). doi:10.2174/1574886312666170523154548. PMID 28545357.
- ^ Bernat AL, Bonnin S, Labidi M, Aldahak N, Bresson D, Bouazza S, Froelich S (2018). "Regression of Giant Olfactory Groove Meningioma and Complete Visual Acuity Recovery after Discontinuation of Cyproterone Acetate". J Ophthalmic Vis Res. 13 (3): 355–358. doi:10.4103/jovr.jovr_21_17. PMC 6058554. PMID 30090195.
- ^ Boer, Mirra; Moernaut, Loes; Van Calenbergh, Frank; Lapauw, Bruno; T'Sjoen, Guy (2018). "Variation of meningioma in response to cyproterone acetate in a trans woman". International Journal of Transgenderism. 19 (1): 92–94. doi:10.1080/15532739.2017.1413615. ISSN 1553-2739. S2CID 148986470.
- ^ a b Mancini I, Rotilio A, Coati I, Seracchioli R, Martelli V, Meriggiola MC (June 2018). "Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review". Gynecol. Endocrinol. 34 (6): 456–459. doi:10.1080/09513590.2017.1395839. PMID 29105524. S2CID 20655235.
- ^ Nizar, Hisham; Seal, Leighton (2018). "Unusual cause of meningioma". Endocrine Abstracts. doi:10.1530/endoabs.59.EP75. ISSN 1479-6848. S2CID 59204730.
- ^ a b Raj R, Korja M, Koroknay-Pál P, Niemelä M (2018). "Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: A report of two cases and a brief literature review". Surg Neurol Int. 9: 109. doi:10.4103/sni.sni_22_18. PMC 5991277. PMID 29930875.
- ^ Chasseur, P; Bruneau, M; Corvilain, B (2019). "A case of meningioma after cyproterone acetate use". Endocrine Abstracts. doi:10.1530/endoabs.64.024. ISSN 1479-6848. S2CID 208487289.
- ^ Alalade, Andrew; Millward, Christopher; Pal, Piyali; Gilkes, Catherine (2019). "Multiple Skull Base Meningiomata in a Transgender Patient: Case Report and Literature Review". Journal of Neurological Surgery Part B: Skull Base. 80: S1–S244. doi:10.1055/s-0039-1679816. ISSN 2193-634X. S2CID 88082457. 29th Annual Meeting North American Skull Base Society.
- ^ Champagne PO, Passeri T, Froelich S (March 2019). "Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report". Acta Neurochir (Wien). 161 (3): 589–592. doi:10.1007/s00701-018-03782-4. PMID 30666456. S2CID 58573065.
- ^ Owens, Lisa; Halliday, Jane; Kerr, Richard; Franks, Stephen (2019). "A case of meningioma associated with long-term use of cyproterone acetate". Endocrine Abstracts. doi:10.1530/endoabs.62.P36. ISSN 1479-6848. S2CID 145949327.
- ^ Colstrup, Hans; Larsen, Ellen D.; Mollerup, Steen; Tarp, Hanne; Soelberg, Jacob; Rosthøj, Susanne (2020). "Long-term follow-up of 60 incarcerated male sexual offenders pharmacologically castrated with a combination of GnRH agonist and cyproterone acetate". The Journal of Forensic Psychiatry & Psychology. 31 (2): 1–14. doi:10.1080/14789949.2020.1711957. ISSN 1478-9949. S2CID 213099389.
- ^ Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J, Schlienger JL (2008). "Does cyproterone acetate promote multiple meningiomas?". Endocrine Abstracts. 16: P158. ISSN 1470-3947.
- ^ Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA (April 2012). "Hormonal therapies and meningioma: is there a link?". Cancer Epidemiol. 36 (2): 198–205. doi:10.1016/j.canep.2011.08.003. PMID 21943794.
- ^ Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C, Boch AL, Loiseau H, Baussart B, Cazabat L, Raffin-Sanson ML, Sanson M, Kalamarides M (March 2018). "Progestin-associated shift of meningioma mutational landscape". Ann. Oncol. 29 (3): 681–686. doi:10.1093/annonc/mdx763. PMID 29206892.
- ^ Portet, Sylvain; Naoufal, Rania; Tachon, Gaëlle; Simonneau, Adrien; Chalant, Anaïs; Naar, Amir; Milin, Serge; Bataille, Benoit; Karayan-Tapon, Lucie (2019). "Histo-Molecular Characterization of Intracranial Meningiomas Developed in Patients Exposed to High-Dose Cyproterone Acetate, An Antiandrogen Treatment". Neuro-Oncology Advances. doi:10.1093/noajnl/vdz003. ISSN 2632-2498. PMID 32642646.
- ^ Deipolyi AR, Han SJ, Parsa AT (October 2010). "Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy". J Clin Neurosci. 17 (10): 1324–6. doi:10.1016/j.jocn.2010.01.036. PMID 20594855. S2CID 206313070.
- ^ McFarlane T, Zajac JD, Cheung AS (December 2018). "Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review". Clin. Endocrinol. (Oxf). 89 (6): 700–711. doi:10.1111/cen.13835. PMID 30107028. S2CID 52003943.